This morning Zealand Pharma announced they were acquiring the assets of Valeritas. Per a company issued press release;
“Valeritas Holdings, Inc. (NASDAQ: VLRX) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced an agreement to sell substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction contemplates the retention of nearly the entirety of the Valeritas workforce.”
For $23 million and the assumption of certain liabilities Zealand has basically purchased the infrastructure necessary to launch their HypoPal® rescue pen . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.